169280-83-5

Usage

Chemical Properties

White solid

InChI:InChI=1/C11H16N2O3/c1-11(2,3)16-10(15)13-9-5-4-8(7-14)6-12-9/h4-6,14H,7H2,1-3H3,(H,12,13,15)

Upstream product

• 199296-40-7 2-(tert-butyloxycarbonyl)-aminopyridine-5-carboxaldehyde 
• 3167-49-5 6-aminonicotinic acid 
• 39658-41-8 ethyl-6-amino-nicotinate 
• 36052-24-1 methyl 6-aminonicotinoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 169280-82-4 6-((tert-butoxycarbonyl)amino)nicotinic acid ethyl ester 
• 1089330-72-2 ethyl 6-[bis(tert-butoxycarbonyl)amino]nicotinate 
• 144186-11-8 methyl 6-<(tert-butyloxycarbonyl)amino>nicotinoate 

Downstream Products

• 144186-12-9 carbonic acid 6-tert-butoxycarbonylamino-pyridin-3-ylmethyl ester 4-nitro-phenyl ester 
• 1196073-33-2 TH-1254 
• 199296-40-7 2-(tert-butyloxycarbonyl)-aminopyridine-5-carboxaldehyde 
• 1585145-51-2 7-(2,6-dichloro-3,5-dimethoxyphenyl)-N-{5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl}isoquinolin-3-amine 
• 1197333-44-0 5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-ylamine 
• 1585145-64-7 7-(2,6-difluoro-3,5-dimethoxyphenyl)-N-{5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl}isoquinolin-3-amine 
• 1585145-71-6 7-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-N-[5-(4-methylpiperazin-1-ylmethyl)pyridin-2-yl]isoquinolin-3-amine 
• 1588422-80-3 3-(2,6-difluorophenyl)-1-ethyl-7-((5-((4-methylpiperazin-1-yl)methyl)pyridin-2-yl)amino)-1,6-naphthyridin-2(1H)-one 
• 1197331-07-9 8-(3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-amide 
• 497159-99-6 dimethyl 2-({6-[(tert-butoxycarbonyl)amino]pyridin-3-yl}methyl)-2-{1-[(4-methylphenyl)sulfonyl]-1H-imidazol-4-yl}malonate 

Relevant academic research and scientific papers

SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS

Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

3-(ARYL- OR HETEROARYL-AMINO)-7-(3,5-DIMETHOXYPHENYL)ISOQUINOLINE DERIVATIVES AS FGFR INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS OR DYSPLASIA

The invention relates to compounds of formula (I) wherein R1, R2, R2a, R3 have the meaning as cited in the description and the claims. Said compounds are useful as FGFR inhibitors. The invention also relates to

MULTIPLE KINASE PATHWAY INHIBITORS

Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.

SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS

Provided herein are novel substituted bicyclic aza-heterocycle sirtuin- modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin- modulating compound in combination with another therapeutic agent.

BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS

Provided herein are sirtuin-modulating compounds of formula (II) The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS

The invention relates to compounds of Formula (I), wherein the substituens are as defined in the specification, in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof; processes for the preparation thereof; to p

Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa)

A series of 3-mercapto-propionic acid derivatives that function as reversible inhibitors of carboxypeptidase U have been prepared. We present a successful design strategy using cyclic, low basicity guanidine mimetics resulting in potent, selective and bioavailable inhibitors of carboxypeptidase U (TAFIa).

Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P′1 group

Structural modifications of the aminopyridine P1 ′ group of imidazole acetic acid based TAFIa inhibitors led to the discovery of the aminocyclopentyl analog 28, a 1nM TAFIa inhibitor with CLT50 functional activity of 14nM but without selectivity against CPB. While not as active, aminobutyl derivative 27 provided an improved 6.7-fold selectivity for TAFIa versus CPB.

alpha - and beta -amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

alpha - and beta -amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors

PCT No. PCT/US94/09139 Sec. 371 Date Jan. 24, 1996 Sec. 102(e) Date Jan. 24, 1996 PCT Filed Aug. 23, 1994 PCT Pub. No. WO95/06030 PCT Pub. Date Mar. 2, 1995The invention relates to sulfonamide-containing hydroxyethylamine protease inhibitor compounds, their process of making, composition and method of use for inhibiting retroviral proteases such as human immunodeficiency virus.